SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'ev2ebit' BDSX (Biodesix) EV-to-EBIT
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » EV-to-EBIT

Biodesix (Biodesix) EV-to-EBIT

: -4.16 (As of Today)
View and export this data going back to 2020. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biodesix's Enterprise Value is $177.32 Mil. Biodesix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-42.61 Mil. Therefore, Biodesix's EV-to-EBIT for today is -4.16.

The historical rank and industry rank for Biodesix's EV-to-EBIT or its related term are showing as below:

BDSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.87   Med: -2.77   Max: -0.71
Current: -4.27

During the past 6 years, the highest EV-to-EBIT of Biodesix was -0.71. The lowest was -29.87. And the median was -2.77.

BDSX's EV-to-EBIT is ranked worse than
100% of 109 companies
in the Medical Diagnostics & Research industry
Industry Median: 18.95 vs BDSX: -4.27

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Biodesix's Enterprise Value for the quarter that ended in Dec. 2023 was $211.48 Mil. Biodesix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-42.61 Mil. Biodesix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -20.15%.

Biodesix EV-to-EBIT Historical Data

The historical data trend for Biodesix's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only - -21.10 -3.63 -2.92 -4.96

Biodesix Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.92 -2.68 -2.23 -3.30 -4.96
Competitive Comparison

For the Diagnostics & Research subindustry, Biodesix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biodesix EV-to-EBIT Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biodesix's EV-to-EBIT falls into.


Biodesix EV-to-EBIT Calculation

Biodesix's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=177.324/-42.61
=-4.16

Biodesix's current Enterprise Value is $177.32 Mil.
Biodesix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodesix  (NAS:BDSX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Biodesix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-42.61/211.481056
=-20.15 %

Biodesix's Enterprise Value for the quarter that ended in Dec. 2023 was $211.48 Mil.
Biodesix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodesix EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Biodesix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biodesix (Biodesix) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » EV-to-EBIT
Comparable Companies
GTH BNR FONR PRPH ENZ NVTA LAB PRE VNRX SERA TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH
Traded in Other Exchanges
N/A
Address
2970 Wilderness Place, Suite 100, Boulder, CO, USA, 80301
Website
https://www.biodesix.com
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Executives
Scott Hutton director, officer: President & CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane officer: Chief Commercial Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano officer: Chief Development Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie officer: CFO, Sec'y & Treasurer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez officer: Chief Accounting Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Jon Faiz Kayyem director 5964 LA PLACE COURT, CARLSBAD CA 92008
Kennedy Lawrence T. Jr director, 10 percent owner C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Ryan H Siurek officer: Chief Accounting Officer 6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
John Patience director, 10 percent owner, other: Chairman 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Georgantas Robert William Iii director, officer: SVP, Rsrch & Trans'l Science 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139